OTC drug review
Is targeted for completion in about two years, FDA Advisor to the Commissioner Mary Pendergast told the Food and Drug Law Institute Dec. 10. "We agreed with the staff of the over-the- counter drug division that 19 years was long enough for the OTC review and we gave that office additional staffing and stature within the FDA," she remarked. "We set our sights on completing the review in a little more than two years not the seven or eight they thought it might take". . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth